Roche, Tecentriq, Tecentriq Hybreza, Atezolizumab, FDA Approval, Stage III Colon Cancer, dMMR, Mismatch Repair Deficiency, ATOMIC Study, Phase 3 Clinical Trial, Immunotherapy,

BASEL, Switzerland — October 9, 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the U.S. Food and Drug...